Aliskiren/amlodipine/hydrochlorothiazide: Difference between revisions

{{Short description|Pharmaceutical drug}}

{{Use dmy dates|date=November 2019}}

{{Infobox drug

| verifiedrevid = 451608217

<!-- Combo data-->

<!-- Clinical data -->

| tradename = Amturnide

| Drugs.com = {{drugs.com|cons|aliskiren-amlodipine-and-hydrochlorothiazide}}

| MedlinePlus =

| DailyMedID = Amturnide

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = [[Oral administration|By mouth]]

| ATC_supplemental =

<!-- Legal status -->

| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->

| legal_AU_comment =

| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->

| legal_BR_comment =

| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_CA_comment =

| legal_DE = <!-- Anlage I, II, III or Unscheduled -->

| legal_DE_comment =

| legal_NZ = <!-- Class A, B, C -->

| legal_NZ_comment =

| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = <ref name="Amturnide FDA label">{{cite web | title=Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010 | website=DailyMed | date=10 November 2016 | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=237747 | access-date=6 February 2022}}</ref>

| legal_EU =

| legal_EU_comment =

| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->

| legal_UN_comment =

| legal_status = <!-- For countries not listed above -->

<!-- Identifiers -->

| CAS_number =

| CAS_supplemental =

| PubChem = 56841821

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D10291

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

<!-- Chemical and physical data -->

| IUPAC_name =

| C=57 | H=86 | Cl=2 | N=8 | O=15 | S=2

| SMILES = CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl

| StdInChI = 1S/C30H53N3O6.C20H25ClN2O5.C7H8ClN3O4S2/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);5-8,17,23H,4,9-11,22H2,1-3H3;1-2,10-11H,3H2,(H2,9,12,13)/t22-,23+,24-,25-;;/m0../s1

| StdInChI_comment =

| StdInChIKey = YJDDFLDXUPNQTO-WMEHTASQSA-N

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

'''Aliskiren/amlodipine/hydrochlorothiazide''', sold under the brand name '''Amturnide''', is a [[fixed-dose combination]] medication that is used to treat high blood pressure.<ref name="Amturnide FDA label" /><ref name="Neutel_2013">{{cite journal | vauthors = Neutel JM, Smith DH | title = Hypertension management: rationale for triple therapy based on mechanisms of action | journal = Cardiovascular Therapeutics | volume = 31 | issue = 5 | pages = 251–8 | date = October 2013 | pmid = 23121769 | doi = 10.1111/1755-5922.12015 }}</ref> It contains [[aliskiren]], a [[renin inhibitor]]; [[amlodipine]], as the [[besylate]], a [[calcium channel blocker]]; and [[hydrochlorothiazide]], a [[thiazide diuretic]].<ref name="Amturnide FDA label" /> It is taken [[Oral administration|by mouth]].<ref name="Amturnide FDA label" />

It was approved for medical use in the United States in December 2010.<ref name="Amturnide FDA label" /><ref>{{cite web | title=Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010 | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=237747 | access-date=5 July 2024}}</ref><ref>{{cite web | title=Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045 | website=U.S. [[Food and Drug Administration]] (FDA) | date=15 August 2011 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200045s000_amturnide_toc.cfm | access-date=27 August 2020}}

*{{lay source |template=cite web |title=Center for Drug Evaluation and Research: Application Number: 200045Orig1s000: Summary review |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200045Orig1s000SumR.pdf |website=Food and Drug Administration}}</ref> Amturnide was withdrawn by Novartis from the US market in 2017.<ref>{{cite web | title=Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications | website=Federal Register | date=21 June 2017 | url=https://www.federalregister.gov/documents/2017/06/21/2017-12908/wyeth-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-121-new-drug-applications-and-161 | access-date=6 February 2022}}</ref>

* {{cite web | title=FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna) | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 June 2021 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warning-and-contraindication-blood-pressure-medicines-containing }}

{{Portal bar | Medicine}}

{{DEFAULTSORT:Aliskiren Amlodipine Hydrochlorothiazide}}

[[Category:Combination antihypertensive drugs]]

[[Category:Drugs developed by Novartis]]

[[Category:Withdrawn drugs]]